Introduction Erectile dysfunction (ED) has a dual negative impact on men and their female partners; both are likely to face a drop in sexual quality of life and challenges to their intimate relationship as couples’ sexual activities are curtailed by the loss of erectile function. Aim The primary objective of this study was to compare the efficacy of vardenafil vs. placebo in terms of success of maintenance of erection in men with ED and improvement of their female partner’s sexual quality of life. Methods This was a randomized, double–blind, multicenter, flexible–dose, parallel–group comparison of vardenafil vs. placebo for 12 weeks in men (≥18 years) with ED of ≥ 6 months duration, and their female partners. Main Outcome Measures Changes in patient’s overall response rate to Sexual Encounter Profile question 3 (SEP3) “Did your erection last long enough for you to have sexual intercourse?” and female partner’s response to the quality of life domain of the modified Sexual Life Quality Questionnaire (mSLQQ–QOL) at last observation carried forward (LOCF) were considered the primary efficacy measures. In addition, patient’s response to SEP2 “Were you able to insert your penis into your partner’s vagina?,” the erectile function domain of the International Index of Erectile Function (IIEF–EF) and patient’s mSLQQ–QOL score were also assessed. Results Compared with placebo, vardenafil significantly improved overall least square (LS) mean per–patient SEP3 success rate (28% vs. 68%; P < 0.0001) and partner’s LS mean (standard error [SE]) mSLQQ–QOL score at LOCF (32.14 [3.24] vs. 65.80 [3.10]; P < 0.0001). In addition, compared with placebo, vardenafil also improved overall LS mean per–patient SEP2 success rate (47% vs. 80%; P < 0.0001), LS mean (SE) IIEF–EF scores at LOCF (12.7 [0.8] vs. 22.8 [0.8]; P < 0.0001) and patient’s LS mean (SE) mSLQQ–QOL (28.37 [3.46] vs. 63.85 [3.28]; P < 0.0001) at LOCF. Conclusions Vardenafil improved erectile function in men with ED and improved the sexual quality of life of the couple.

In men with severe ED after nerve sparing radical retropubic prostatectomy, vardenafil significantly improved key indices of erectile function.

Introduction There are limited data concerning the sexual function of women whose male partners receive pharmacological treatment for erectile dysfunction (ED). Aim One objective of this research was to prospectively compare the efficacy of vardenafil vs. placebo administered to men with ED in improving men's and women partners’ sexual function and satisfaction. Another goal was to assess the relationship of erectile function changes in men with ED receiving treatment with sexual function changes in women partners not directly receiving treatment. Methods A randomized, double-blind, placebo-controlled, multi-institutional comparison of vardenafil vs. placebo was performed in 229 couples (treated man with ED >6 months and untreated woman partner). Co-primary outcomes for which this research was statistically powered were Sexual Encounter Profile (SEP3) (treated man with ED) and Sexual Life Quality Questionnaire (mSLQQ-QOL) (untreated woman partner). Main Outcome Measures Erectile function changes in men with ED receiving vardenafil vs. placebo were compared at last observation carried forward (LOCF) in SEP3, International Index of Erectile Function (IIEF-EF) and Erection Quality Scale (EQS). Sexual function at LOCF in women partners was determined by mSLQQ-QOL and Female Sexual Function Index (FSFI). Results Compared with placebo at LOCF, vardenafil significantly increased least square (LS) mean scores in: (i) overall per-treated male SEP3 success rate, IIEF-EF, and EQS; and (ii) mSLQQ-QOL, total FSFI and sexual desire, subjective arousal, lubrication, orgasm and satisfaction FSFI domains in untreated women partners. Treatment-related improvement in erectile function as assessed by IIEF-EF and EQS was correlated reliably with improvement in women partners’ FSFI total and individual domain scores. Conclusions Vardenafil is an effective ED treatment in men that also significantly improves sexual function/satisfaction in untreated women partners. Women partners’ sexual function improvements relate significantly and consistently to treatment-related improvements in men's erectile function. ED management should emphasize both members of the couple.

LA-2585 (45.0 mg depot) consistently produced and maintained safe and effective serum testosterone suppression with total serum testosterone well below the medical castrate level of less than 50 ng/dl.

No abstract